Mahlangu, JohnnyJohnnyMahlanguKaczmarek, RadoslawRadoslawKaczmarekvon Drygalski, AnnetteAnnettevon DrygalskiShapiro, SusanSusanShapiroSHENG-CHIEH CHOUOzelo, Margareth CMargareth COzeloKenet, GiliGiliKenetPeyvandi, FloraFloraPeyvandiWang, MichaelMichaelWangMadan, BellaBellaMadanKey, Nigel SNigel SKeyLaffan, MichaelMichaelLaffanDunn, Amy LAmy LDunnMason, JaneJaneMasonQuon, Doris VDoris VQuonSymington, EmilyEmilySymingtonLeavitt, Andrew DAndrew DLeavittOldenburg, JohannesJohannesOldenburgChambost, HervéHervéChambostReding, Mark TMark TRedingJayaram, KalaKalaJayaramYu, HuaHuaYuMahajan, ReenaReenaMahajanChavele, Konstantia-MariaKonstantia-MariaChaveleReddy, Divya BDivya BReddyHenshaw, JoshuaJoshuaHenshawRobinson, Tara MTara MRobinsonWong, Wing YenWing YenWongPipe, Steven WSteven WPipe2023-06-142023-06-142023-02-2300284793https://scholars.lib.ntu.edu.tw/handle/123456789/632673Valoctocogene roxaparvovec delivers a B-domain-deleted factor VIII coding sequence with an adeno-associated virus vector to prevent bleeding in persons with severe hemophilia A. The findings of a phase 3 study of the efficacy and safety of valoctocogene roxaparvovec therapy evaluated after 52 weeks in men with severe hemophilia A have been published previously.enCoagulation | Genetics | Genetics General | Hematology/Oncology[SDGs]SDG3journal article10.1056/NEJMoa2211075368124332-s2.0-85149465324